Pediatrics
Final Professional MBBS — Pediatrics. Complete question bank: Long Questions (10 marks) and Short Notes (5 marks) across all 15 systems, with clinical pearls, drug doses, staging tables, mnemonics and key-point recaps.
DEFINITION
The Universal Immunisation Programme (UIP) is India's national programme providing free vaccines against vaccine-preventable diseases to all children and pregnant women. Immunisation is one of the most cost-effective public-health interventions.
NATIONAL IMMUNISATION SCHEDULE
Age Vaccines Birth BCG, OPV-0, Hepatitis B (birth dose < 24 h) 6 weeks OPV-1, Pentavalent-1 (DPT+HepB+Hib), Rotavirus-1, fIPV-1, PCV-1 10 weeks OPV-2, Pentavalent-2, Rotavirus-2 14 weeks OPV-3, Pentavalent-3, Rotavirus-3, fIPV-2, PCV-2 9–12 months Measles/MR-1, PCV-booster, JE-1 (endemic), Vitamin A (1st) 16–24 months MR-2, DPT-booster-1, OPV-booster, JE-2, Vitamin A 5–6 years DPT-booster-2 10 & 16 years Td Pregnancy Td (2 doses or a booster) KEY VACCINE-PREVENTABLE DISEASES COVERED
- Tuberculosis (severe forms), poliomyelitis, diphtheria, pertussis, tetanus (including neonatal/maternal).
- Hepatitis B, Haemophilus influenzae type b disease, measles, rubella, rotaviral diarrhoea, pneumococcal disease, and Japanese encephalitis (endemic areas).
OBJECTIVES OF THE UIP
- Reduce morbidity and mortality from vaccine-preventable diseases.
- Achieve and sustain high coverage; work toward elimination/eradication (polio, measles-rubella, neonatal tetanus).
ROUTES & SITES OF ADMINISTRATION
Vaccine Route/site BCG Intradermal, left upper arm OPV, Rotavirus Oral Pentavalent, PCV, JE, Hep B IM, anterolateral thigh Measles/MR Subcutaneous Td IM, deltoid (older) EVALUATION OF THE PROGRAMME
- Fully immunised child — all due vaccines received by 1 year (measles by 9–12 months).
- Coverage evaluation surveys; drop-out rates (e.g. Penta-1 to Penta-3).
IAP (OFFICE-PRACTICE) ADDITIONAL VACCINES
- Beyond the UIP, the IAP recommends additional/optional vaccines for those who can afford them — e.g. hepatitis A, varicella, typhoid conjugate, influenza, HPV, meningococcal.
- HPV for adolescent girls (cervical cancer prevention) is increasingly emphasised.
VACCINE-PREVENTABLE DISEASE BURDEN
The UIP has driven dramatic declines in diphtheria, neonatal tetanus, measles and polio; sustaining high coverage and reaching the unreached remain the key challenges.
COMMON REASONS FOR DROP-OUT / LOW COVERAGE
- Lack of awareness, fear of AEFIs, false contraindications, and access/logistic barriers.
- Migration and 'hard-to-reach' populations; addressed by outreach, Mission Indradhanush and communication.
SPECIAL CAMPAIGNS
Alongside routine immunisation, campaigns such as Pulse Polio and Intensified Mission Indradhanush boost coverage and target unreached children to close immunity gaps.
MISSED OPPORTUNITIES & CATCH-UP
Every health-facility contact should be used to give any due vaccine; withholding for false contraindications creates missed opportunities. An interrupted schedule is resumed from where it stopped (never restarted), with catch-up as per guidelines.
BENEFITS OF THE PROGRAMME
- Prevents death and disability from vaccine-preventable diseases at very low cost.
- Contributes to elimination/eradication goals and reduces health-system burden.
ELEMENTS OF A SUCCESSFUL PROGRAMME
- Reliable vaccine supply and cold chain; trained staff and safe injection practices.
- Community demand generation and record-keeping (immunisation cards, digital registries); monitoring and evaluation of coverage.
💊KEY DOSES / ROUTES (viva)- BCG 0.05 mL (newborn)/0.1 mL — intradermal, left upper arm.
- OPV 2 drops oral; Rotavirus 5 drops oral.
- Pentavalent/DPT/PCV/JE/Hep B — intramuscular (anterolateral thigh in infants).
- Measles/MR 0.5 mL subcutaneous.
PRINCIPLES OF SCHEDULING
- Give all due vaccines at a visit (no false contraindications); minimum intervals between doses must be respected.
- An interrupted schedule is resumed, not restarted; catch-up as per guidelines.
📝CLINICAL / APPLIED POINTS- Learn the schedule as a table — examiners frequently ask 'what is given at 14 weeks?'.
- Only the birth dose of hepatitis B and OPV-0 are given at birth alongside BCG.
- Never restart an interrupted schedule — continue from where it stopped.
- Use every contact to catch up missed vaccines (avoid 'missed opportunities').
- Maternal Td protects against maternal and neonatal tetanus — a key programme success.
🔑KEY POINTS TO REMEMBER- UIP = free national immunisation for children and pregnant women.
- Birth: BCG + OPV-0 + Hep B; 6/10/14 wk: pentavalent + OPV + rotavirus (± fIPV/PCV).
- 9–12 mo: MR-1; 16–24 mo: MR-2 + boosters; 5–6 yr & 10/16 yr boosters.
- Routes: BCG intradermal, OPV/rota oral, MR subcutaneous, rest intramuscular.
- Resume (don't restart) interrupted schedules; use every contact for catch-up.
📚SOURCES: Ghai Essential Pediatrics; IAP/UIP National Immunisation Schedule.BASIS — ACTIVE vs PASSIVE IMMUNITY
Feature Active immunity Passive immunity Source Infection or vaccine Preformed antibodies Onset Slow (days–weeks) Immediate Duration Long-lasting (memory) Short (weeks–months) Example Vaccines Immunoglobulins, maternal antibodies CLASSIFICATION OF VACCINES
- Live attenuated — BCG, OPV, measles/MR/MMR, rotavirus, varicella, live JE, yellow fever.
- Inactivated/killed — IPV, whole-cell pertussis, hepatitis A, rabies, cholera.
- Toxoids — diphtheria and tetanus (inactivated toxins).
- Subunit / conjugate / recombinant — Hib, pneumococcal (PCV), meningococcal, recombinant hepatitis B, HPV, acellular pertussis.
LIVE vs INACTIVATED VACCINES
Feature Live attenuated Inactivated/killed Immunity Strong, often lifelong (1–2 doses) Weaker; needs multiple doses/boosters Immune response Humoral + cell-mediated Mainly humoral In immunocompromised/pregnancy Generally contraindicated Safe Cold chain More heat-sensitive More stable ⚠️DANGER / REMEMBER: Live vaccines are generally contraindicated in significant immunodeficiency and pregnancy (risk of the attenuated organism causing disease). Multiple live vaccines can be given on the same day, but if not, separate them by ~4 weeks.HERD IMMUNITY
When a high proportion of a population is immunised, transmission is interrupted and even the unimmunised are protected — herd immunity — the basis of disease elimination/eradication programmes.
THE IMMUNE RESPONSE TO VACCINATION
- Primary response — after the first dose; slow, mainly IgM, low titre.
- Secondary (booster) response — rapid, high-titre IgG from memory cells; the basis of booster doses.
ADJUVANTS & COMBINATION VACCINES
- Adjuvants (e.g. aluminium salts) enhance the immune response to inactivated antigens.
- Combination vaccines (pentavalent, MMR) reduce the number of injections and improve compliance.
ROUTES OF VACCINE ADMINISTRATION
- Oral (OPV, rotavirus), intradermal (BCG), subcutaneous (measles/MR), intramuscular (most inactivated/toxoid/conjugate).
- Correct route is essential for efficacy and safety.
COLD-CHAIN & STABILITY IMPLICATIONS
The vaccine type determines storage needs — live vaccines are generally more heat-labile (careful cold chain, VVM monitoring), whereas adsorbed inactivated/toxoid vaccines must not be frozen; this links vaccine science directly to programme logistics.
SPACING & CO-ADMINISTRATION
- Most vaccines can be co-administered at different sites on the same day.
- Two live parenteral vaccines, if not given together, are separated by ~4 weeks.
VACCINE FAILURE
- Primary failure — the vaccine does not induce an adequate initial response (e.g. host/immune factors, or cold-chain breach).
- Secondary failure — immunity wanes over time (a reason for boosters).
KEY EXAM POINT
Being able to classify any named vaccine (live/killed/toxoid/conjugate) and state its route and cold-chain sensitivity is high-yield — the type predicts immunity, dosing, safety in special groups and storage.
REPRESENTATIVE VACCINES BY CLASS (quick table)
Class Examples Live attenuated BCG, OPV, MR/MMR, rotavirus, varicella, JE (live) Inactivated/killed IPV, whole-cell pertussis, rabies, hepatitis A, cholera Toxoid Diphtheria, tetanus Conjugate/subunit/recombinant Hib, PCV, meningococcal, Hep B, HPV, aP WHY VACCINES NEED SPECIFIC SCHEDULES
Dosing schedules balance the infant's developing immune system, the decline of protective maternal antibodies, and the disease risk by age — hence, for example, measles vaccination at 9 months (when maternal antibody has waned) and the birth dose of hepatitis B (to pre-empt perinatal transmission).
SPECIAL GROUPS
- Immunocompromised children — avoid live vaccines; give inactivated vaccines (may need extra doses).
- Preterm infants are vaccinated by chronological age; pregnancy — inactivated vaccines/toxoids are safe, live vaccines avoided.
📝CLINICAL / APPLIED POINTS- Classify a named vaccine correctly (live vs killed vs toxoid vs conjugate) — a favourite viva question.
- Live vaccines give durable immunity but are risky in immunodeficiency/pregnancy.
- Toxoid vaccines (tetanus, diphtheria) protect against the toxin, not the organism.
- Conjugation (Hib, PCV) makes polysaccharide antigens immunogenic in infants.
- Herd immunity explains why high coverage protects the whole community.
🔑KEY POINTS TO REMEMBER- Active (vaccine/infection; slow, lasting) vs passive (antibodies; immediate, short).
- Live: BCG, OPV, MR/MMR, rotavirus, varicella; killed: IPV, rabies, hepatitis A.
- Toxoid: diphtheria, tetanus; conjugate/subunit: Hib, PCV, Hep B, HPV.
- Live vaccines contraindicated in immunodeficiency/pregnancy; more heat-sensitive.
- High coverage → herd immunity → disease elimination/eradication.
📚SOURCES: Ghai Essential Pediatrics; Park's Textbook of Preventive & Social Medicine.DEFINITION
The cold chain is the system of storing and transporting vaccines at the recommended low temperature from the point of manufacture to the point of administration, so that their potency is preserved.
COLD-CHAIN EQUIPMENT
- Walk-in coolers/freezers and deep freezers (regional/district stores).
- Ice-lined refrigerator (ILR) — stores vaccines at 2–8 °C at the health-facility level.
- Cold boxes and vaccine carriers with ice packs for transport and outreach sessions.
STORAGE TEMPERATURES
- Most vaccines are stored at 2–8 °C (in the ILR).
- OPV (and measles at higher levels) may be kept frozen (−15 to −25 °C) in deep freezers; at the facility they are used from the ILR.
VACCINE SENSITIVITY
Type Vaccines Note Most HEAT-sensitive OPV > measles/MR > BCG Store carefully; watch VVM FREEZE-sensitive (must NOT freeze) DPT, Hep B, TT/Td, IPV, pentavalent, PCV Freezing destroys potency MONITORING TOOLS
- Vaccine Vial Monitor (VVM) — a heat-sensitive label that changes colour with cumulative heat exposure (discard if the inner square is as dark as the outer).
- Shake test — detects freeze damage in adsorbed (DPT/Hep B) vaccines.
- Temperature charts/data loggers; contingency plans for power failure.
⚠️DANGER / REMEMBER: Freeze-sensitive vaccines (DPT, hepatitis B, TT, IPV, pentavalent) are irreversibly damaged by freezing — never store them touching ice packs or in the freezer compartment; use conditioned ice packs.LEVELS OF THE COLD CHAIN
Primary store (national/GMSD) → State/regional vaccine store (walk-in cooler/freezer) → District store → PHC/health facility (ILR + deep freezer) → Session site (vaccine carrier with ice packs)
OPENED-VIAL POLICY & WASTAGE
- Certain multi-dose vaccines (e.g. OPV, some liquid vaccines) may be used in later sessions if conditions are met (open-vial policy); reconstituted vaccines (BCG, measles) must be discarded after a few hours.
- Minimising wastage while maintaining potency is a programme priority.
POWER FAILURE & CONTINGENCY
- Keep the ILR closed, use conditioned ice packs, and monitor temperature; have a backup plan/generator.
- Twice-daily temperature recording detects breaches early.
ROLE OF THE VACCINE VIAL MONITOR (detail)
The VVM has an inner square that darkens with cumulative heat exposure; when it matches or is darker than the outer circle, the vial is discarded. It allows vaccines to be used safely up to the point of heat-damage and reduces unnecessary wastage.
TEMPERATURE MONITORING
- Twice-daily temperature recording (morning and evening) on a chart; alarm/logger systems where available.
- Immediate corrective action and reporting for any excursion outside 2–8 °C.
CONSEQUENCES OF A BROKEN COLD CHAIN
- Loss of potency → vaccine failure without any visible change in most vaccines.
- Freeze-damaged adsorbed vaccines can also cause more local reactions; heat-damaged live vaccines simply fail.
KEY EXAM POINT
Two memory hooks: OPV is the most heat-sensitive vaccine, and DPT/Hep B/TT/IPV are the freeze-sensitive ones that must never be frozen; the VVM (heat) and shake test (freeze) are the bedside checks.
COLD-CHAIN 'DOs AND DON'Ts'
- Do — keep the ILR at 2–8 °C, record temperature twice daily, use conditioned ice packs, and monitor VVMs.
- Don't — freeze DPT/Hep B/TT/IPV, open the ILR unnecessarily, or use vaccines past their VVM end-point/expiry.
IMPORTANCE FOR VACCINE EFFICACY
Because a broken cold chain reduces potency invisibly (in most vaccines), maintaining it is as important as the vaccine itself — a fully 'immunised' child given heat-damaged vaccine may remain unprotected, which is why VVMs, the shake test and temperature logs are integral to the programme.
SUMMARY
The cold chain links vaccine science to field practice — without an intact 2–8 °C chain (freeze-sensitive vaccines never frozen), even correctly scheduled vaccines fail silently; VVMs, the shake test and diligent temperature monitoring safeguard potency.
KEY EXAM POINT (recap)
OPV is the most heat-sensitive vaccine; DPT/Hep B/TT/IPV are freeze-sensitive and must never be frozen.
📝CLINICAL / APPLIED POINTS- Remember the two lists — heat-sensitive (OPV, measles, BCG) and freeze-sensitive (DPT, Hep B, TT, IPV).
- The VVM tells you at a glance whether a vial has had too much heat exposure.
- The shake test detects freeze-damaged adsorbed vaccines (they fail to re-suspend uniformly).
- A broken cold chain silently reduces potency — vaccine failure without any visible sign.
- Store vaccines in the ILR (2–8 °C); never let freeze-sensitive vaccines freeze.
🔑KEY POINTS TO REMEMBER- Cold chain = temperature-controlled storage/transport preserving vaccine potency.
- Equipment: walk-in cooler/freezer, ILR (2–8 °C), deep freezer, cold boxes, carriers.
- Heat-sensitive: OPV > measles > BCG; freeze-sensitive: DPT, Hep B, TT, IPV, penta.
- Monitor with VVM and the shake test; keep temperature logs.
- Never freeze freeze-sensitive vaccines — freezing irreversibly destroys potency.
📚SOURCES: Ghai Essential Pediatrics; Park's Textbook of Preventive & Social Medicine.DEFINITION
An Adverse Event Following Immunisation (AEFI) is any untoward medical occurrence which follows immunisation and does not necessarily have a causal relationship with the vaccine. Robust AEFI surveillance maintains public trust in immunisation.
WHO CLASSIFICATION (by cause)
Category Description Vaccine product-related Due to the vaccine's inherent properties (e.g. fever after DPT) Vaccine quality defect-related Due to a manufacturing/quality defect Immunisation error-related Programmatic error (wrong dose/site, non-sterile injection, wrong diluent) Immunisation anxiety-related Anxiety about the injection (e.g. vasovagal fainting) Coincidental Unrelated event happening by chance after immunisation COMMON AEFIs
- Minor (common) — fever, local pain/redness/swelling, irritability (usually self-limiting).
- Severe/serious — anaphylaxis, seizures, persistent screaming, injection abscess, BCG lymphadenitis/disseminated BCG, VAPP.
MANAGEMENT
- Minor — reassurance, antipyretics, local care.
- Anaphylaxis — immediate intramuscular adrenaline, airway/oxygen, IV fluids (every session must have an anaphylaxis kit).
- Reporting and investigation — notify serious/clustered AEFIs through the surveillance system; investigate to determine causality and correct programmatic errors.
CAUSALITY ASSESSMENT
Serious AEFIs are investigated and classified (consistent causal association, indeterminate, coincidental, or unclassifiable) using a structured WHO framework, so that genuine vaccine reactions are separated from coincidental events and programmatic errors.
SURVEILLANCE STRUCTURE
- Reporting from the periphery upward, with district/state AEFI committees reviewing serious events.
- The goal is early detection, correct response, and maintenance of public confidence.
SPECIFIC EXAMPLES
- Injection abscess/cluster → suspect an immunisation (sterility) error.
- BCG lymphadenitis/disseminated BCG → consider underlying immunodeficiency; VAPP → OPV-related.
MINOR vs SERIOUS AEFI (summary)
Type Examples Action Minor Fever, local reaction, irritability Reassurance, antipyretic Serious Anaphylaxis, seizures, abscess, disseminated BCG Treat urgently + report + investigate MAINTAINING PUBLIC CONFIDENCE
Transparent reporting, prompt management, and clear communication about coincidental vs genuine reactions are essential — misattributed AEFIs can undermine an entire immunisation programme.
KEY PRINCIPLES OF AEFI RESPONSE
Treat the patient (e.g. adrenaline for anaphylaxis) → Report through the surveillance system → Investigate serious/clustered events → Assess causality → Correct any programmatic error & communicate
KEY EXAM POINT
Most AEFIs are minor and coincidental; the programme's job is to treat serious events promptly (anaphylaxis kit at every session), report and investigate them, and maintain public trust through transparent causality assessment.
EXAMPLES BY WHO CATEGORY (quick table)
Category Example Product-related Fever after DPT; BCG lymphadenitis Quality defect Reaction from a defective batch Immunisation error Abscess from a non-sterile injection; wrong diluent Anxiety-related Fainting (vasovagal) after injection Coincidental Febrile illness by chance after vaccination WHY AEFI SURVEILLANCE MATTERS
Effective AEFI surveillance protects children (by detecting genuine safety signals and programmatic errors) and protects the programme (by countering misinformation), thereby sustaining the public confidence on which high coverage depends.
💊KEY DOSES / ROUTES (viva)- Adrenaline (anaphylaxis) 0.01 mg/kg of 1:1000 IM (max 0.5 mg), repeat every 5–15 min as needed.
- Antipyretic (paracetamol 15 mg/kg) for fever/pain.
PREVENTION OF PROGRAMMATIC ERRORS
- Correct technique — right vaccine, dose, site, route, diluent; one sterile syringe per child (AD syringes).
- Proper reconstitution and use within the recommended time; cold-chain maintenance; trained staff.
📝CLINICAL / APPLIED POINTS- Most AEFIs are minor and self-limiting — reassurance and antipyretics suffice.
- Every immunisation session must be ready to treat anaphylaxis with IM adrenaline.
- Immunisation-error AEFIs are preventable — correct site/dose/diluent and sterile injection.
- Report and investigate serious/clustered events to preserve programme credibility.
- A clear AEFI is not automatically 'the vaccine's fault' — causality is assessed systematically.
🔑KEY POINTS TO REMEMBER- AEFI = any untoward event after immunisation (not necessarily causal).
- WHO causes: product-related, quality-defect, immunisation-error, anxiety-related, coincidental.
- Minor (fever, local reaction) common; serious — anaphylaxis, seizures, BCG lymphadenitis.
- Anaphylaxis → IM adrenaline 0.01 mg/kg; report/investigate serious events.
- Prevent programmatic errors with correct technique, sterile injection and cold chain.
📚SOURCES: Ghai Essential Pediatrics; WHO AEFI classification; UIP guidelines.DEFINITION
Poliomyelitis is an acute viral infection caused by the poliovirus (an enterovirus, types 1–3), spread by the faeco-oral route. It can damage anterior horn cells of the spinal cord, causing acute flaccid paralysis (AFP).
CLINICAL FEATURES
- Most infections are asymptomatic/minor (fever, sore throat).
- Paralytic polio — asymmetric, flaccid, lower-motor-neuron paralysis with intact sensation; may involve respiratory/bulbar muscles.
- Residual weakness/deformity in survivors; post-polio syndrome later.
OPV vs IPV
Feature OPV (oral) IPV (injectable) Type Live attenuated Inactivated (killed) Route Oral Intramuscular Gut (mucosal) immunity Yes (blocks transmission) No Herd effect Strong Limited Risk Rare VAPP / VDPV None (no live virus) Cost/ease Cheap, easy mass use More expensive POLIO ERADICATION STRATEGY
- High routine immunisation coverage plus supplementary Pulse Polio (National Immunisation Days).
- Acute flaccid paralysis (AFP) surveillance — investigate every case of AFP in children under 15 (stool for poliovirus) to detect any wild/vaccine-derived virus.
- The 'endgame' switch — from trivalent to bivalent OPV and introduction of IPV to withdraw live virus safely.
💡CLINICAL PEARL: India was certified polio-free in 2014 (and the WHO South-East Asia Region shortly after) — a major public-health achievement driven by Pulse Polio campaigns and AFP surveillance.VACCINE-ASSOCIATED RISKS
- VAPP — vaccine-associated paralytic polio (very rare, from the live OPV strain).
- VDPV — vaccine-derived polioviruses that can regain neurovirulence/circulate in under-immunised populations — a reason for the eventual switch to IPV.
PATHOGENESIS
The virus multiplies in the pharynx and gut, then may spread to the CNS and destroy the anterior horn cells of the spinal cord (and sometimes brainstem), producing lower-motor-neuron paralysis with intact sensation.
CLINICAL TYPES
- Spinal — asymmetric limb weakness (commonest paralytic form).
- Bulbar — cranial nerve/respiratory involvement (dangerous); bulbospinal.
DIFFERENTIAL DIAGNOSIS OF AFP
- Guillain-Barré syndrome (symmetric, areflexia, sensory), transverse myelitis (sensory level, sphincter involvement), traumatic neuritis.
- All AFP is investigated to exclude poliovirus.
POST-POLIO SYNDROME
Years after acute paralytic polio, some survivors develop new muscle weakness, fatigue and pain (post-polio syndrome) in previously affected or unaffected muscles; management is supportive.
GLOBAL & NATIONAL STATUS
- Global eradication is close — wild poliovirus remains in very few countries; type 2 and type 3 wild virus have been certified eradicated.
- India's success (polio-free 2014) rests on sustained surveillance and immunisation to prevent re-importation.
PREVENTION & CONTROL SUMMARY
- High routine OPV/IPV coverage, Pulse Polio supplementary immunisation, strong AFP surveillance, and environmental (sewage) surveillance.
- Maintaining these prevents re-importation now that India is polio-free.
KEY EXAM POINT
Poliomyelitis causes asymmetric, flaccid, lower-motor-neuron paralysis with intact sensation; OPV gives gut immunity and herd protection, IPV avoids VAPP/VDPV, and eradication rests on coverage plus AFP surveillance.
OPV vs IPV — SUMMARY OF THE 'ENDGAME'
- The eradication endgame reduces reliance on live OPV (which carries rare VAPP/VDPV risk) by introducing IPV and switching OPV formulations.
- IPV provides individual humoral protection safely; OPV's gut immunity and herd effect remain valuable during transition.
SIGNIFICANCE OF AFP SURVEILLANCE
Sensitive AFP surveillance — investigating every case of acute flaccid paralysis in children under 15 with stool testing — is the backbone of certifying and maintaining polio-free status, ensuring that any wild or vaccine-derived poliovirus is detected and contained promptly.
SUMMARY
Polio control combines OPV (gut immunity, herd effect) and IPV (safe humoral immunity) with Pulse Polio campaigns and AFP surveillance; sustaining these prevents re-importation now that India is polio-free (2014).
📝CLINICAL / APPLIED POINTS- Polio causes asymmetric flaccid paralysis with preserved sensation — distinguish from GBS (symmetric) and other AFP causes.
- Every child with AFP must be reported and investigated to exclude poliovirus.
- OPV gives gut immunity and herd protection; IPV avoids the rare VAPP/VDPV risk.
- Pulse Polio + AFP surveillance were the pillars of India's polio-free success (2014).
- The endgame moves away from live OPV toward IPV to eliminate vaccine-derived risk.
🔑KEY POINTS TO REMEMBER- Poliovirus (enterovirus) → faeco-oral → asymmetric flaccid LMN paralysis (sensation intact).
- OPV: live, oral, gut immunity + herd effect, rare VAPP/VDPV; IPV: killed, IM, no live-virus risk.
- Strategy: high coverage + Pulse Polio + AFP surveillance; endgame switch to IPV.
- India certified polio-free in 2014.
- Every AFP case under 15 years must be investigated for poliovirus.
📚SOURCES: Ghai Essential Pediatrics; Nelson Textbook of Pediatrics; National Polio Surveillance Project.DEFINITION
BCG (Bacille Calmette-Guérin) is a live attenuated vaccine (from Mycobacterium bovis) that protects children against the severe forms of tuberculosis (miliary TB and TB meningitis).
ADMINISTRATION
- Given at birth (or at first contact) as part of the UIP.
- Intradermal injection of 0.05 mL (newborn) / 0.1 mL (older) over the left upper arm (deltoid).
- A correct intradermal dose produces a wheal, then over weeks a papule → ulcer → healed scar (a marker of successful vaccination).
COMPLICATIONS
- Local — injection abscess, prolonged ulceration, regional (axillary) lymphadenitis.
- Disseminated BCG (BCG-osis) in immunocompromised infants — hence caution in known immunodeficiency.
MECHANISM & EFFICACY
BCG induces cell-mediated immunity against mycobacteria; it does not reliably prevent primary infection or adult pulmonary TB but substantially reduces severe disseminated forms (miliary TB, TB meningitis) in young children.
KEY EXAM POINT
A correctly placed intradermal dose raises a wheal and later forms a scar; the absence of a scar may prompt re-vaccination per programme policy. Avoid BCG in known significant immunodeficiency (risk of disseminated BCG).
COMPLICATIONS IN DETAIL
- Most complications are local and self-limiting (abscess, ulcer, small lymph node).
- Suppurative lymphadenitis may need aspiration; disseminated BCG requires anti-tubercular therapy and immunological evaluation.
KEY POINTS RECAP
- Live attenuated; intradermal; protects against severe childhood TB; forms a scar.
- Caution/avoid in significant immunodeficiency (disseminated BCG risk).
PROGRAMME NOTE
BCG is one of the most widely used vaccines worldwide and is given as early as possible after birth in high-TB-burden countries such as India, because it prevents the most dangerous childhood forms of tuberculosis.
SUMMARY
As a live intradermal vaccine given at birth to prevent severe childhood TB, BCG exemplifies the value of early immunisation in a high-burden setting; the resulting scar is a useful marker of vaccination.
EXAM RELEVANCE
This is a frequently asked short note — remember the vaccine type/route, its place in the UIP schedule, and its key precautions or programmatic significance.
🔑KEY POINTS TO REMEMBER- Live attenuated vaccine; protects against severe TB (miliary, TBM).
- At birth; 0.05/0.1 mL intradermal over the left deltoid; forms a scar.
- Complications: abscess, axillary lymphadenitis, disseminated BCG (immunocompromised).
- Does not prevent primary infection — protects against severe childhood forms.
📚SOURCES: Ghai Essential Pediatrics; UIP guidelines.DEFINITION
The measles-containing vaccine is a live attenuated vaccine given as MR (measles-rubella) in the UIP, or as MMR (measles-mumps-rubella), to protect against these diseases and support measles/rubella elimination.
ADMINISTRATION
- Two doses — the first at 9–12 months and the second at 16–24 months (Indian schedule).
- 0.5 mL subcutaneously; the two doses ensure protection in those who did not respond to the first.
PRECAUTIONS & AEFIs
- Being live, it is avoided in significant immunodeficiency and pregnancy.
- Minor AEFIs — fever and a mild rash 5–12 days later; rarely febrile seizures.
INDICATIONS & CATCH-UP
Any child who has missed the doses should receive catch-up MR/MMR; the vaccine is also used for outbreak control and post-exposure prophylaxis (within 72 hours of measles exposure).
KEY EXAM POINT
Two doses of a measles-containing vaccine are needed for reliable protection and are central to measles and rubella elimination goals; being live, it is deferred in pregnancy and significant immunodeficiency.
STORAGE & HANDLING
- Live vaccine — maintain the cold chain; reconstituted vaccine must be used within a few hours and then discarded.
- Protect from light; avoid freezing the diluent-reconstituted product beyond the permitted window.
KEY POINTS RECAP
- Live; two doses (9–12 and 16–24 months); subcutaneous; central to elimination.
- Avoid in pregnancy/immunodeficiency; can be used for post-exposure prophylaxis.
PROGRAMME NOTE
India has adopted measles-rubella (MR) vaccine campaigns and two routine doses to accelerate progress toward measles and rubella (and congenital rubella syndrome) elimination.
SUMMARY
A live subcutaneous vaccine given in two doses, the measles-containing vaccine is the key tool for measles and rubella elimination, with post-exposure use within 72 hours of measles exposure.
EXAM RELEVANCE
This is a frequently asked short note — remember the vaccine type/route, its place in the UIP schedule, and its key precautions or programmatic significance.
🔑KEY POINTS TO REMEMBER- Live attenuated; given as MR (UIP) or MMR.
- Two doses: 9–12 months and 16–24 months; 0.5 mL subcutaneous.
- Avoid in immunodeficiency/pregnancy; mild fever/rash may follow.
- Two doses are key to measles/rubella elimination.
📚SOURCES: Ghai Essential Pediatrics; UIP guidelines.DEFINITION
DPT protects against diphtheria (toxoid), pertussis (whole-cell or acellular) and tetanus (toxoid). In the UIP the primary series is given as the pentavalent vaccine (DPT + hepatitis B + Hib).
SCHEDULE & ROUTE
- Primary series (pentavalent) at 6, 10 and 14 weeks; DPT boosters at 16–24 months and 5–6 years.
- Intramuscular (anterolateral thigh in infants).
- Later tetanus/diphtheria protection is boosted with Td at 10 and 16 years and in pregnancy.
AEFIs & NOTES
- Local pain/swelling and fever are common (more with whole-cell pertussis); acellular pertussis causes fewer reactions.
- Pertussis component is omitted (DT/Td) if there is a clear contraindication.
COMPONENTS & VARIANTS
- Whole-cell pertussis (wP) — more reactogenic; acellular pertussis (aP) — fewer reactions.
- DT (no pertussis) for those with a pertussis contraindication; Td (reduced diphtheria) for older children/adults.
KEY EXAM POINT
The pentavalent vaccine (DPT+HepB+Hib) delivers five antigens in one injection at 6/10/14 weeks, reducing injections and improving compliance, with DPT boosters later.
PROTECTION & BOOSTERS
The primary series builds protection, and boosters at 16–24 months and 5–6 years (then Td later) maintain immunity against diphtheria and tetanus into adolescence and pregnancy; maternal Td prevents neonatal tetanus.
KEY POINTS RECAP
- Diphtheria/tetanus toxoids + pertussis; given as pentavalent at 6/10/14 weeks; IM.
- Boosters at 16–24 months and 5–6 years; Td later and in pregnancy.
PROGRAMME NOTE
The pentavalent vaccine replaced separate DPT, hepatitis B and Hib injections in the UIP, cutting the number of pricks while broadening protection — a key programmatic improvement.
SUMMARY
DPT (as pentavalent) provides the infant primary series against diphtheria, pertussis and tetanus, with well-timed boosters maintaining immunity — and maternal Td preventing neonatal tetanus.
EXAM RELEVANCE
This is a frequently asked short note — remember the vaccine type/route, its place in the UIP schedule, and its key precautions or programmatic significance.
🔑KEY POINTS TO REMEMBER- DPT = diphtheria toxoid + pertussis + tetanus toxoid; given as pentavalent (+HepB+Hib) in UIP.
- Primary at 6/10/14 weeks; boosters at 16–24 months and 5–6 years; IM.
- Td at 10 & 16 years and in pregnancy.
- Local reactions/fever common (whole-cell pertussis); acellular is less reactogenic.
📚SOURCES: Ghai Essential Pediatrics; UIP guidelines.DEFINITION
The hepatitis B vaccine is a recombinant (subunit) vaccine that protects against hepatitis B virus infection and its complications (chronic hepatitis, cirrhosis, hepatocellular carcinoma).
SCHEDULE & ROUTE
- Birth dose within 24 hours (crucial to prevent perinatal/vertical transmission), then as part of the pentavalent vaccine at 6, 10 and 14 weeks.
- Intramuscular (anterolateral thigh).
KEY POINTS & SPECIAL SITUATIONS
- Infants of HBsAg-positive mothers should receive the birth dose (and, where available, hepatitis B immunoglobulin) promptly.
- A highly effective, safe vaccine; provides long-lasting protection.
SIGNIFICANCE OF THE BIRTH DOSE
A timely birth dose (within 24 hours) is the single most important measure to prevent perinatal (mother-to-child) transmission, which otherwise leads to a high rate of chronic carriage and later cirrhosis/liver cancer.
KEY EXAM POINT
For a baby born to an HBsAg-positive mother, give the hepatitis B vaccine birth dose (and hepatitis B immunoglobulin where available) as soon as possible after birth.
STORAGE & PROGRAMME NOTE
Hepatitis B vaccine is freeze-sensitive (do not freeze). Its inclusion in the pentavalent vaccine simplifies the schedule while the separate birth dose ensures early protection against perinatal transmission.
KEY POINTS RECAP
- Recombinant; birth dose < 24 h + pentavalent; prevents perinatal transmission.
- Freeze-sensitive — do not freeze; give HBIG to newborns of HBsAg+ mothers where available.
PROGRAMME NOTE
Universal hepatitis B vaccination (birth dose plus pentavalent) aims to reduce the pool of chronic carriers and, in the long term, the burden of cirrhosis and liver cancer.
SUMMARY
A safe recombinant vaccine, hepatitis B vaccination — anchored by the timely birth dose — is central to preventing chronic hepatitis B and its serious long-term liver complications.
EXAM RELEVANCE
This is a frequently asked short note — remember the vaccine type/route, its place in the UIP schedule, and its key precautions or programmatic significance.
🔑KEY POINTS TO REMEMBER- Recombinant vaccine preventing hepatitis B (and its long-term liver complications).
- Birth dose < 24 h (prevents perinatal transmission) + pentavalent at 6/10/14 weeks; IM.
- Infants of HBsAg-positive mothers — prompt birth dose ± HBIG.
- Safe and highly effective, with durable protection.
📚SOURCES: Ghai Essential Pediatrics; UIP guidelines.ROTAVIRUS VACCINE
- Live, oral vaccine against rotavirus — the commonest cause of severe infantile gastroenteritis.
- Given at 6, 10 and 14 weeks; must complete within the recommended age window.
- A small risk of intussusception is noted — avoid a first dose in older infants; counsel on warning signs.
PNEUMOCOCCAL CONJUGATE VACCINE (PCV)
- A conjugate vaccine against Streptococcus pneumoniae — prevents pneumonia, meningitis and sepsis.
- Given as a primary series with a booster around 9 months (UIP schedule).
SIGNIFICANCE
Rotavirus and PCV target the two biggest infectious killers of under-fives (diarrhoea and pneumonia), and their inclusion in the UIP is a major child-survival advance.
WHY THEY MATTER
Diarrhoea and pneumonia are the two leading infectious causes of under-five death; rotavirus and pneumococcal vaccines directly target them, making their addition to the UIP a major child-survival intervention.
KEY EXAM POINT
Rotavirus vaccine is live and oral with age limits for the first dose (intussusception risk); PCV is a conjugate vaccine protecting against pneumococcal pneumonia, meningitis and sepsis.
ROTAVIRUS — PRACTICAL POINTS
- Complete the schedule within the recommended age window; counsel families about intussusception warning signs (blood in stool, severe crying, vomiting).
- Being live and oral, it contributes to reducing severe, dehydrating gastroenteritis.
KEY POINTS RECAP
- Rotavirus — live oral, 6/10/14 weeks, small intussusception risk.
- PCV — conjugate, primary + booster; both target the leading under-5 killers.
PROGRAMME NOTE
The phased introduction of rotavirus and pneumococcal conjugate vaccines into the UIP reflects a strategy of directly tackling the two commonest infectious causes of under-five mortality.
SUMMARY
Rotavirus and pneumococcal conjugate vaccines are recent, high-impact additions to the UIP that directly reduce the two leading infectious causes of under-five death — diarrhoea and pneumonia.
EXAM RELEVANCE
This is a frequently asked short note — remember the vaccine type/route, its place in the UIP schedule, and its key precautions or programmatic significance.
🔑KEY POINTS TO REMEMBER- Rotavirus — live oral, 6/10/14 weeks; small intussusception risk; prevents severe diarrhoea.
- PCV — conjugate; primary + ~9-month booster; prevents pneumonia/meningitis/sepsis.
- Both target the leading under-5 killers (diarrhoea and pneumonia).
- Important recent additions to the UIP.
📚SOURCES: Ghai Essential Pediatrics; UIP guidelines.DEFINITION
Passive immunisation is the administration of preformed antibodies, giving immediate but temporary protection (no immunological memory).
SOURCES / TYPES
- Natural — transplacental maternal antibodies; antibodies in breast milk.
- Immunoglobulins — normal human Ig, and specific Ig (hepatitis B Ig, tetanus Ig, VZIG, rabies Ig).
- Antisera/antitoxins — anti-tetanus serum, anti-diphtheria serum, anti-snake venom.
USES
- Post-exposure prophylaxis (tetanus-prone wounds, rabies, hepatitis B exposure, varicella in high-risk contacts).
- Treatment (diphtheria antitoxin, snake envenomation) and in immunodeficiency.
ACTIVE vs PASSIVE (contrast)
Unlike active immunisation (which is slow but durable), passive immunisation gives immediate protection but lasts only weeks to months and confers no memory; the two are often combined (e.g. tetanus immunoglobulin PLUS toxoid).
KEY EXAM POINT
Passive immunisation is the treatment/prophylaxis of choice when protection is needed immediately — e.g. anti-snake venom for envenomation, rabies immunoglobulin and tetanus immunoglobulin for high-risk exposures, and in immunodeficiency.
EXAMPLES OF SPECIFIC IMMUNOGLOBULINS
- HBIG — hepatitis B exposure/newborn of HBsAg+ mother; TIG — tetanus-prone wounds.
- VZIG — varicella exposure in high-risk contacts; rabies Ig — category III animal bites (with vaccine).
KEY POINTS RECAP
- Preformed antibodies → immediate, short-lived protection, no memory.
- Uses: post-exposure prophylaxis (TIG, HBIG, VZIG, rabies Ig), antitoxin/antivenom, immunodeficiency.
PROGRAMME NOTE
Passive and active immunisation are complementary — for a tetanus-prone wound in an unimmunised person, tetanus immunoglobulin gives immediate cover while tetanus toxoid builds lasting immunity.
SUMMARY
Passive immunisation buys immediate protection when there is no time to build active immunity, and is often paired with active immunisation (e.g. immunoglobulin plus toxoid/vaccine) for both immediate and lasting cover.
🔑KEY POINTS TO REMEMBER- Passive = preformed antibodies; immediate but short-lived (no memory).
- Types: maternal/breast-milk antibodies, immunoglobulins (HBIG, TIG, VZIG, RIG), antisera/antitoxins.
- Uses: post-exposure prophylaxis, treatment (antitoxin/antivenom), immunodeficiency.
- Often combined with active immunisation (e.g. TIG + tetanus toxoid).
📚SOURCES: Ghai Essential Pediatrics; Park's Textbook of Preventive & Social Medicine.TRUE CONTRAINDICATIONS
- Anaphylaxis to a previous dose or to a vaccine component.
- Live vaccines — significant immunodeficiency and pregnancy.
- Encephalopathy within 7 days of a pertussis dose (for the pertussis component); deferring in acute severe illness.
FALSE CONTRAINDICATIONS (myths — do NOT withhold vaccines)
- Minor illness or low-grade fever, mild diarrhoea; malnutrition.
- Breastfeeding, prematurity/low birth weight, current antibiotic use, and a family history of AEFI/allergy.
- Withholding vaccines for these reasons creates 'missed opportunities'.
MISSED OPPORTUNITIES
A 'missed opportunity' is any contact with a health service where an eligible child does not receive a due vaccine. Using every contact to vaccinate (and giving all due vaccines together) improves coverage.
PRACTICAL IMPLICATIONS
Adhering to true contraindications (and ignoring the false ones) maximises safe coverage; every eligible contact is an opportunity to vaccinate, and vaccines due together should be given together.
KEY EXAM POINT
A child with a mild cold, low-grade fever, mild diarrhoea or on antibiotics can and should be vaccinated — withholding vaccines for these 'false contraindications' is a common, avoidable cause of under-immunisation.
DEFERRAL vs CONTRAINDICATION
A truly contraindicated vaccine is withheld; a vaccine is merely deferred (not cancelled) in acute moderate/severe illness and given once the child recovers — an important distinction that prevents permanent under-immunisation.
KEY POINTS RECAP
- True: anaphylaxis to a prior dose/component; live vaccines in immunodeficiency/pregnancy.
- False (do not withhold): mild illness/low-grade fever, malnutrition, breastfeeding, prematurity, antibiotics.
PROGRAMME NOTE
Reducing missed opportunities by respecting only true contraindications is one of the simplest, most effective ways to raise immunisation coverage and protect more children.
SUMMARY
Distinguishing true from false contraindications, and using every contact to vaccinate, are simple, high-yield ways to avoid missed opportunities and improve coverage and equity.
🔑KEY POINTS TO REMEMBER- True contraindications: anaphylaxis to a prior dose/component; live vaccines in immunodeficiency/pregnancy.
- False contraindications: mild illness/low-grade fever, malnutrition, breastfeeding, prematurity, antibiotics.
- Do not withhold vaccines for false contraindications — avoid 'missed opportunities'.
- Use every health contact to give all due vaccines.
📚SOURCES: Ghai Essential Pediatrics; IAP/UIP guidelines.